Castle Bio Prices IPO at $16 per Share

Jul 25, 2019

|

NEW YORK — Skin cancer test developer Castle Biosciences said today that it has priced its planned initial public offering at $16 a share, the top end of the previously disclosed range.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Castle Bio Prices IPO at $16 per Share

To read the full story....

Breaking News

FDA Issues Emergency Use Authorization for University of Nebraska Medical Center Coronavirus Test

Oxford Immunotec Shares Rise Sharply on Report of $400M Acquisition Offer

Medix Biochemica Acquires US Firms EastCoast Bio, Biostride

HHS Releases Data Reporting Guidance for Labs Performing SARS-CoV-2 Testing

Opti Medical Systems Gets CE Mark for Coronavirus Test Kit

AACC Revises Guidance on Management of Point-of-Care Testing

Featured White Papers

Diagnostic Challenges in Cancer Immunotherapy: An Expert Panel Discussion

What's Popular?

Labs Launching Employer SARS-CoV-2 Testing Programs as Businesses Reopen

HHS Releases Data Reporting Guidance for Labs Performing SARS-CoV-2 Testing

CDC Develops Test for Simultaneous Detection of COVID-19, Flu

Beset by COVID-19 Pandemic, Europe Searches for Right Test Mix for Diagnosis, Surveillance

At-Home Coronavirus Tests Get Nod From FDA But Agency Proceeding With Caution

Sponsorships